STOCK TITAN
  1. Home
  2. News
  3. INVO

INVO Bioscience Inc - INVO STOCK NEWS

Welcome to our dedicated news page for INVO Bioscience (Ticker: INVO), a resource for investors and traders seeking the latest updates and insights on INVO Bioscience.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INVO Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INVO Bioscience's position in the market.

News
INVO Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
INVO Bioscience, Inc. (INVO) reports significant revenue growth in Q4 2023 and FY 2023, with a focus on expanding access to advanced fertility treatments. The company's revenue increased by 397% in Q4 and 267% in FY 2023, driven by clinic revenue growth and strategic acquisitions. Despite a net loss, adjusted EBITDA improved, reflecting a positive outlook for future profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
139.47%
Tags
earnings
-
News
NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal
Rhea-AI Summary
NAYA Biosciences Inc. (NAYA) announces new data for its CD38-targeted Flex-NK™ Bispecific Antibody (NY-338, formerly CYT-338) for the treatment of Multiple Myeloma (MM) published as an abstract in the 2023 American Society of Hematology's (ASH) meeting supplement of Blood. The data demonstrates a differentiated profile from DARZALEX® (daratumumab) with best-in-class potential, supporting the initiation of clinical trials in 2024. NAYA expects to close its previously announced merger with INVO Bioscience (NASDAQ: INVO) in the first quarter of 2024. NAYA aims to establish an expanded, publicly-traded life science company dedicated to increasing patient access to breakthrough treatments in fertility, oncology, and regenerative medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
none
-
News
NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies
Rhea-AI Summary
NAYA Biosciences Inc. (NAYA) partners with ONK Therapeutics to evaluate combination therapy for cancer treatment. The partnership aims to assess the proof-of-concept and feasibility of using NAYA's FLEX-NK™ bispecific antibodies and ONK's engineered natural killer (NK) cells to address the unmet medical need in hepatocellular carcinoma (HCC). NAYA is also set to close its merger with INVO Bioscience (NASDAQ: INVO) in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
partnership
News
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
Rhea-AI Summary
INVO Bioscience (INVO) regained compliance with Nasdaq's minimum stockholders' equity requirement, receiving a notice from Nasdaq on November 22, 2023. The company entered into a share exchange agreement with Cytovia Therapeutics Holdings, Inc. for the acquisition of 1,200,000 shares of newly designated Series B Preferred Stock, resulting in a significant reduction in net loss and sufficient stockholders' equity to maintain its Nasdaq listing. INVO also announced a definitive merger agreement with NAYA Biosciences in an all-stock transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.02%
Tags
none
-
News
INVO Reports Record Third Quarter 2023 Financial Results
Rhea-AI Summary
INVO Bioscience, Inc. (Nasdaq: INVO) Expects to Host Conference Call Shortly After November 20, 2023 Following the Progress of Certain Closing Conditions Pertaining to the Announced Merger Agreement with NAYA Biosciences. Q3 2023 Financial Highlights show a 314% increase in revenues, adjusted EBITDA improvement, and a partial quarter contribution from the recently acquired Wisconsin Fertility Institute. INVO and NAYA Biosciences Inc. have entered into a definitive merger agreement for INVO to acquire NAYA Biosciences in an all-stock transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.16%
Tags
earnings
-
News
NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger
Rhea-AI Summary
INVO Bioscience, Inc. (INVO) and NAYA Biosciences Inc. announce Dr. Peter Kash, Ed.D., MBA as Vice Chairman of the combined company's Board of Directors. The merger will focus on expanding access to advanced fertility treatment and increasing patient access to breakthrough treatments in oncology and regenerative medicine. Dr. Kash brings over 36 years of leadership experience in the biotech industry and a track record of cofounding and financing several biotech companies. His appointment is expected to accelerate the development and commercialization of life-changing therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
90.68%
Tags
management acquisition
News
INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company's Common Stock Purchase Warrants
Rhea-AI Summary
INVO Bioscience, Inc. (Nasdaq: INVO) announced the solicitation of waivers from holders of the Company's common stock purchase warrants dated August 8, 2023, as a condition to the consummation of the proposed merger with NAYA Biosciences, Inc. The Waiver Solicitation is scheduled to expire on November 15, 2023. Important Additional Information will be filed with the SEC in connection with the Proposed Transaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
90.68%
Tags
none
-
News
Free Registration Is Now Open For Tribe Public's CEO and Q&A Presentation Webinar Event "Accelerating Biotech Value Creation" Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023
Rhea-AI Summary
NAYA Biosciences CEO Dr. Daniel Teper will present at Tribe Public's Webinar Presentation and Q&A Event on October 31, 2023. NAYA Biosciences aims to increase patient access to breakthrough treatments in oncology, regenerative medicine, and fertility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.8%
Tags
none
-
News
INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life Science Company
Rhea-AI Summary
INVO Bioscience and NAYA Biosciences have entered into a definitive merger agreement for INVO to acquire NAYA in an all-stock transaction. The combined company will be named 'NAYA Biosciences' and will focus on increasing patient access to treatments in oncology, fertility, and regenerative medicine. The merger is valued at $12,373,780 for INVO and $90,750,000 for NAYA. NAYA Oncology has acquired two clinical-stage bispecific antibody assets for the treatment of Hepatocellular Carcinoma and Multiple Myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
292.59%
Tags
acquisition
News
INVO to Participate in the Lytham Partners Fall 2023 Investor Conference
Rhea-AI Summary
INVO Bioscience CEO to participate in panel presentation at Lytham Partners Fall 2023 Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.16%
Tags
conferences
Stock INVO logo
INVO Bioscience Inc

Nasdaq:INVO

INVO Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

INVO Stock Data

2.13M
2.45M
0.89%
4.34%
0.46%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Sarasota

About INVO

with the invocell and invo procedure, invo bioscience allows more and more patients to now receive safe, effective and affordable infertility treatment.